直接PCI时冠状动脉内溶栓治疗ST段抬高型心肌梗死的系统评价与荟萃分析
该系统评价与荟萃分析纳入12项随机对照试验共1915例STEMI患者,评估直接PCI时辅助冠状动脉内溶栓的疗效与安全性。结果显示冠状动脉内溶栓显著降低主要不良心血管事件(RR=0.65,95%CI 0.51-0.82,p<0.0004)并改善左心室射血分数(WMD=1.87,95%CI 1.07-2.67,p<0.0001),且不增加出血事件。
要点
- 冠状动脉内溶栓显著降低MACE风险(RR=0.65),并改善左心室射血分数(WMD=1.87)。
- 非纤维蛋白特异性和中度纤维蛋白特异性溶栓药亚组MACE显著降低,高度纤维蛋白特异性药物亚组无显著降低。
- 全因死亡率和出血事件(大出血、小出血)在两组间无显著差异。
核心结论
- STEMI患者直接PCI时辅助冠状动脉内溶栓可改善临床和心肌灌注参数,且不增加出血率。
- 需进一步研究优化溶栓药物选择和治疗方案。
研究设计与样本
- 系统评价与荟萃分析,检索六个电子数据库识别相关随机对照试验。
- 纳入12项研究共1915例患者。
- 主要结局为主要不良心血管事件(MACE),计算合并风险比(RR)和加权均数差(WMD)及95%CI。
主要发现
- 冠状动脉内溶栓组MACE发生率显著降低(RR=0.65,95%CI 0.51-0.82,I2=0%,p<0.0004)。
- 左心室射血分数显著改善(WMD=1.87,95%CI 1.07-2.67,I2=25%,p<0.0001)。
- 非纤维蛋白特异性溶栓药亚组MACE显著降低(RR=0.39,95%CI 0.20-0.78,I2=0%,p=0.007)。
- 中度纤维蛋白特异性溶栓药亚组MACE显著降低(RR=0.62,95%CI 0.47-0.83,I2=0%,p=0.001)。
- 高度纤维蛋白特异性溶栓药亚组MACE无显著降低(RR=1.10,95%CI 0.62-1.96,I2=0%,p=0.75)。
关键数值与推荐
- 全因死亡率无显著差异(RR=0.91,95%CI 0.48-1.71,I2=0%,p=0.77)。
- 大出血事件无显著差异(RR=1.24,95%CI 0.47-3.28,I2=0%,p=0.67)。
- 小出血事件无显著差异(RR=1.47,95%CI 0.90-2.40,I2=0%,p=0.12)。
临床怎么用
- 对于STEMI行直接PCI的患者,可考虑辅助冠状动脉内溶栓以降低MACE并改善左心室射血分数。
- 选择溶栓药物时需注意纤维蛋白特异性,非纤维蛋白特异性和中度纤维蛋白特异性药物显示获益,高度纤维蛋白特异性药物未显示获益。
- 应用时需评估出血风险,现有证据显示不增加出血事件。
局限性
- 需进一步研究优化溶栓药物选择和治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite restoration of epicardial blood flow in acute ST-elevation myocardial infarction (STEMI), inadequate microcirculatory perfusion is common and portends a poor prognosis. Intracoronary (IC) thrombolytic therapy can reduce microvascular thrombotic burden; however, contemporary studies have produced conflicting outcomes. OBJECTIVES: This meta-analysis aims to evaluate the efficacy and safety of adjunctive IC thrombolytic therapy at the time of primary percutaneous coronary intervention (PCI) among patients with STEMI. METHODS: Comprehensive literature search of six electronic databases identified relevant randomised controlled trials. The primary outcome was major adverse cardiac events (MACE). The pooled risk ratio (RR) and weighted mean difference (WMD) with a 95% CI were calculated. RESULTS: 12 studies with 1915 patients were included. IC thrombolysis was associated with a significantly lower incidence of MACE (RR=0.65, 95% CI 0.51 to 0.82, I2=0%, p<0.0004) and improved left ventricular ejection fraction (WMD=1.87; 95% CI 1.07 to 2.67; I2=25%; p<0.0001). Subgroup analysis demonstrated a significant reduction in MACE for trials using non-fibrin (RR=0.39, 95% CI 0.20 to 0.78, I2=0%, p=0.007) and moderately fibrin-specific thrombolytic agents (RR=0.62, 95% CI 0.47 to 0.83, I2=0%, p=0.001). No significant reduction was observed in studies using highly fibrin-specific thrombolytic agents (RR=1.10, 95% CI 0.62 to 1.96, I2=0%, p=0.75). Furthermore, there were no significant differences in mortality (RR=0.91; 95% CI 0.48 to 1.71; I2=0%; p=0.77) or bleeding events (major bleeding, RR=1.24; 95% CI 0.47 to 3.28; I2=0%; p=0.67; minor bleeding, RR=1.47; 95% CI 0.90 to 2.40; I2=0%; p=0.12). CONCLUSION: Adjunctive IC thrombolysis at the time of primary PCI in patients with STEMI improves clinical and myocardial perfusion parameters without an increased rate of bleeding. Further research is needed to optimise the selection of thrombolytic agents and treatment protocols.
引用
- Rehan, Virk, Wong, et al. Intracoronary thrombolysis in ST-elevation myocardial infarction: a systematic review and meta-analysis. Heart. 2024. PMID: 38925881. doi:10.1136/heartjnl-2024-324078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。